Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective.
Kaplan DE, Serper M, Kaushik A, Durkin C, Raad A, El-Moustaid F, Smith N, Yehoshua A.
Kaplan DE, et al. Among authors: kaushik a.
J Manag Care Spec Pharm. 2022 Oct;28(10):1138-1148. doi: 10.18553/jmcp.2022.28.10.1138.
J Manag Care Spec Pharm. 2022.
PMID: 36125059
Free PMC article.
METHODS: A hybrid decision-tree and Markov model simulated the health outcomes of a cohort of 142,147 patients with HCV with an average age of 63 years. ...Treatment costs and utility values were sourced from publicly available databases and prior publications for o …
METHODS: A hybrid decision-tree and Markov model simulated the health outcomes of a cohort of 142,147 patients with HCV with a …